Title:
COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN ANTI-OBESITY AGENT
Document Type and Number:
WIPO Patent Application WO2004096132
Kind Code:
A3
Abstract:
A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a therapeutically-effective amount of an anti-obesity agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred anti-obesity agents are those compounds having high potency and bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha, 11alpha- substituted epoxy moiety.
Inventors:
GULVE ERIC ARTHUR (US)
MCMAHON ELLEN GARWITZ (US)
MCMAHON ELLEN GARWITZ (US)
Application Number:
PCT/US2004/012205
Publication Date:
June 09, 2005
Filing Date:
April 20, 2004
Export Citation:
Assignee:
PHARMACIA CORP (US)
GULVE ERIC ARTHUR (US)
MCMAHON ELLEN GARWITZ (US)
GULVE ERIC ARTHUR (US)
MCMAHON ELLEN GARWITZ (US)
International Classes:
A61K45/06; (IPC1-7): A61K31/585
Domestic Patent References:
| WO2000027380A2 | 2000-05-18 | |||
| WO2003099279A1 | 2003-12-04 |
Foreign References:
| US6620821B2 | 2003-09-16 | |||
| US6391867B2 | 2002-05-21 | |||
| US0455932A | 1891-07-14 |
Other References:
See also references of EP 1633370A4
Download PDF:
Previous Patent: INHIBITORS OF AKT ACTIVITY
Next Patent: METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1
Next Patent: METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1